Anifrolumab Infusion Product + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Dec 15, 2023 → May 1, 2026
NCT ID
NCT05917561About Anifrolumab Infusion Product + Placebo
Anifrolumab Infusion Product + Placebo is a phase 2 stage product being developed by AstraZeneca for Vitiligo. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05917561. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05917561 | Phase 2 | Recruiting |
Competing Products
20 competing products in Vitiligo